Greenwood Capital Associates LLC cut its stake in iCAD, Inc. (NASDAQ:ICAD - Free Report) by 89.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,545 shares of the technology company's stock after selling 243,935 shares during the period. Greenwood Capital Associates LLC owned approximately 0.10% of iCAD worth $59,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Thompson Davis & CO. Inc. acquired a new position in iCAD in the 4th quarter valued at $31,000. PKS Advisory Services LLC acquired a new position in iCAD in the 4th quarter valued at $53,000. Wells Fargo & Company MN raised its holdings in iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock valued at $72,000 after acquiring an additional 13,402 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in iCAD in the 4th quarter valued at $92,000. Finally, Granahan Investment Management LLC acquired a new position in iCAD in the 4th quarter valued at $96,000. 24.61% of the stock is owned by institutional investors and hedge funds.
iCAD Stock Performance
Shares of iCAD stock traded up $0.15 during trading on Monday, reaching $3.83. 370,180 shares of the company's stock were exchanged, compared to its average volume of 421,925. iCAD, Inc. has a 1-year low of $1.18 and a 1-year high of $4.02. The company has a market cap of $105.21 million, a P/E ratio of -29.46 and a beta of 1.38. The firm's 50-day moving average price is $3.41 and its 200 day moving average price is $2.69.
iCAD (NASDAQ:ICAD - Get Free Report) last issued its earnings results on Tuesday, May 13th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The business had revenue of $4.87 million during the quarter, compared to analysts' expectations of $4.54 million.
Wall Street Analysts Forecast Growth
ICAD has been the subject of a number of research analyst reports. BTIG Research cut iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th. Laidlaw reissued a "hold" rating on shares of iCAD in a report on Thursday, April 17th. Craig Hallum cut iCAD from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Finally, Wall Street Zen initiated coverage on iCAD in a report on Tuesday, May 20th. They set a "sell" rating for the company.
Check Out Our Latest Stock Report on ICAD
iCAD Company Profile
(
Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
Before you consider icad, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and icad wasn't on the list.
While icad currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
